Sana Biotechnology, Inc. is a clinical-stage biotechnology company developing novel cell therapies for the treatment of a range of serious diseases. The company is developing platforms that can repair and control genes in cells or replace any cell in the body. Sana's fusogen platform is designed to optimize in vivo cell specific delivery of genetic material. The goal is to be able to repair and control genes in cells. Engineering cells in vivo requires the development of both an appropriate delivery vehicle, as well as an active component to effectively modify the target cell. Fusogens are naturally occurring cell-targeting proteins. Sana reengineers these proteins to target specific cell surface receptors, enabling cell-specific delivery to many different types of cells. Sana's hypoimmune platform is designed to create cells ex vivo that can "hide" from the patient's immune system to enable the transplant of allogeneic cells without the need for immunosuppression. Sana is applying hypoimmune technology to both donor-derived allogeneic T cells, with the goal of making potent and persistent CAR T cells at scale, and pluripotent stem cells, which can then be differentiated into multiple cell types at scale.
